Nebivolol for treatment patients with arterial hypertension

Nebivolol for treatment patients with arterial hypertension

Beta-adrenergic blocking agent is included in the group of primary agentsfor treatment of patients with AH. In the pathogenesis of AH,one of the main causes leading to raisingthe blood pressure isendothelial dysfunction.Correction ofendothelial dysfunctionis AH treatment strategic aim.Nebivololis a...

Full description

Bibliographic Details
Main Authors: O M Mikheeva, I A Komisarenko
Format: Article
Language:Russian
Published: IP Morozov P.V. 2014-09-01
Series:Системные гипертензии
Subjects:
arterial hypertension
β-adrenergic blocking agent
endothelial dysfunction
nebivolol
Online Access:https://syst-hypertension.ru/2075-082X/article/viewFile/29056/pdf
Description
Summary:Beta-adrenergic blocking agent is included in the group of primary agentsfor treatment of patients with AH. In the pathogenesis of AH,one of the main causes leading to raisingthe blood pressure isendothelial dysfunction.Correction ofendothelial dysfunctionis AH treatment strategic aim.Nebivololis a cardioselectivethird-generationvasodilatingβ-adrenergic blocking agent, which is in addition toβ-adrenergic blocking effect, can alsoincrease endogenousproduction of NOin the endothelial cellsdue to the decreasing of oxidative degradation. As a result,nebivololprovides positivehemodynamic effects on patients with AH, decreasingperipheral resistanceandblood pressure.
ISSN:2075-082X
2542-2189

Similar Items